# Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>03</td>
</tr>
<tr>
<td>Our Purpose and Values</td>
<td>04</td>
</tr>
<tr>
<td>Our Values</td>
<td>04</td>
</tr>
<tr>
<td><strong>Our Structure, Operations and Supply Chain</strong></td>
<td>05</td>
</tr>
<tr>
<td>Our Company – Global Snapshot</td>
<td>05</td>
</tr>
<tr>
<td>Our Operations</td>
<td>05</td>
</tr>
<tr>
<td>Our Supply Chain</td>
<td>06</td>
</tr>
<tr>
<td><strong>Risks of Modern Slavery in Pfizer’s Operations and Supply Chain</strong></td>
<td>06</td>
</tr>
<tr>
<td>Our Operations</td>
<td>06</td>
</tr>
<tr>
<td>Supply Chain</td>
<td>07</td>
</tr>
<tr>
<td><strong>Actions taken to assess and address the modern slavery risks</strong></td>
<td>08</td>
</tr>
<tr>
<td>Policies and Governance</td>
<td>08</td>
</tr>
<tr>
<td>Audits</td>
<td>09</td>
</tr>
<tr>
<td>Anti-Bribery and Anti-Corruption</td>
<td>09</td>
</tr>
<tr>
<td>Supplier Conduct Position Statement</td>
<td>10</td>
</tr>
<tr>
<td>Contract Clauses</td>
<td>10</td>
</tr>
<tr>
<td>Training</td>
<td>10</td>
</tr>
<tr>
<td>External Engagement</td>
<td>11</td>
</tr>
<tr>
<td>Specific Examples of Due Diligence</td>
<td>12</td>
</tr>
<tr>
<td>Rubber Gloves</td>
<td>12</td>
</tr>
<tr>
<td>Freight and Logistics</td>
<td>12</td>
</tr>
<tr>
<td>Raising Concerns</td>
<td>12</td>
</tr>
<tr>
<td><strong>UK Modern Slavery Act Signature</strong></td>
<td>14</td>
</tr>
</tbody>
</table>
Introduction

This Modern Slavery Statement (Statement) is for the period from 1 January 2021 to 31 December 2021 and has been prepared pursuant to both the California Transparency in Supply Chains Act and the UK Modern Slavery Act. We prepared a single statement because we generally follow the same policies and procedures globally to address modern slavery.

In relation to Pfizer companies operating in the UK, this Statement has been prepared on behalf of Pfizer Limited and its associated companies:

• Hospira UK Limited
• John Wyeth & Brother Limited
• Pharmacia Limited
• Pfizer Development Services (UK) Limited
• Pfizer R&D UK Limited

In this Statement, “Pfizer” refers to Pfizer Inc. and its subsidiaries.

Modern Slavery is a global problem affecting an estimated 40 million people or more worldwide according to the Global Slavery Index. Modern Slavery as defined by the relevant statutes means exploitative practices including human trafficking, slavery, slavery-like practices, servitude, forced labour, debt bondage, the worst forms of child labour, and deceptive recruiting for labour services. This Statement details the actions we have taken to assess and help address modern slavery risks in our operations and supply chains.
Our Purpose and Values

‘Breakthroughs that change patients’ lives’

Pfizer’s purpose ‘Breakthroughs that change patients’ lives’ fuels everything we do. In 2021, we reached an estimated 1.4 billion patients with our medicines and vaccines.¹

Equity is a core value of our company and has been the north star of our COVID-19 response. It has driven our ongoing collaboration with governments and key stakeholders around the world to work towards fair and equitable access to COVID-19 vaccines and treatments while also providing our expertise and resources for novel approaches to help strengthen healthcare systems where greater support may be needed. To accelerate efforts to reach vulnerable populations, we pledged to provide 2 billion doses of our COVID-19 vaccine to low- and middle-income countries in 2021 and 2022, i.e., at least 1 billion doses year. We fulfilled the first half of this pledge in December 2021, with more than 1 billion doses delivered to 100 low- and middle-income countries.

We innovate every day to help make the world a healthier place. From scientific discovery to breakthrough products to our essential partnerships around the world, we’re committed to quality healthcare for everyone because every individual matters.

Our Values

To fully realise our purpose, we have established a clear set of expectations regarding “what” we need to achieve for patients and “how” we will go about achieving those goals.

The “how” is represented by four simple, powerful values:

![Courage](image1.png)  ![Excellence](image2.png)  ![Equity](image3.png)  ![Joy](image4.png)

In March 2022, Pfizer was named one of the world’s most ethical companies by Ethisphere. This list is a recognition of companies that demonstrate a commitment to ethical business practices through programs that positively impact employees, communities, and broader stakeholders, and contribute to sustainable and profitable long-term business performance.²

¹ Patients counts are estimates derived from multiple data sources
Our Structure, Operations and Supply Chain

Pfizer Inc. is a global company with its headquarters in New York and operations around the world.

Our Company – Global Snapshot

<table>
<thead>
<tr>
<th>Approximately</th>
<th>More than</th>
<th>Approximately</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.4b patients reached with our medicines and vaccines in 2021⁴</td>
<td>39 manufacturing sites and 11 distribution/logistics centres worldwide</td>
<td>125 countries in which Pfizer sells products</td>
</tr>
</tbody>
</table>

Our Operations

Our global manufacturing and supply network includes 39 manufacturing sites across six continents in addition to our research and development, commercial, and logistics operations. Our global manufacturing and research and development sites can be found here.

Our sites operate according to Pfizer’s policies and procedures including those outlined in this Statement. In particular, our Environment, Health & Safety (EHS) policies include topics such as workers’ rights, health and safety, and the protection of the environment. We regularly monitor and review our sites’ performance to help ensure our standards of conduct meet the high expectations we set for ourselves. Our EHS Policy and more information on our EHS governance can be found here. More information about Pfizer’s standards for our direct operations can be found in the Policies & Governance section of this Statement.

Our Supply Chain

At Pfizer, responsible supply chain management is core to how we do business. We operate within a framework of principles aligned with ethical, social, and environmental responsibilities to help ensure sustainability of our business and the communities in which we operate.

A network of external suppliers is essential to enable manufacture of medicines and vaccines that deliver breakthroughs that change patients’ lives. Pfizer’s supply chain supports the research, development, and manufacturing process by providing flexibility and access to technologies necessary to meet our commitment to patients. We are committed to using suppliers that demonstrate strong performance in EHS management.

³ As of December 2021.
⁴ Patient counts are estimates derived from multiple data sources.
Risks of Modern Slavery in Pfizer’s Operations and Supply Chain

Our Operations

For the reasons described below, we believe that the risk of modern slavery in our operations is low.

- Our employees generally are hired on a regular full-time basis, rather than being temporary, seasonal or migrant workers.
- The contractors we engage directly as part of our operations are also generally in highly skilled and professional roles.
- To the extent our manufacturing sites may engage operators through a recruitment agency, we have arrangements with only a small select number of recruitment agencies that are required to satisfy due diligence checks prior to formal engagement and with modern slavery clauses in our standard supplier contracts.
- Except for those engaged in a formal apprentice or internship program, everyone working in our operations is 18 years or older.
- All of our employees are paid in excess of minimum wage.

Supply Chain

In seeking to assess the modern slavery risks in our supply chain, we consider the potential for our business to cause, contribute to, or be directly linked to modern slavery. Our supply chain includes a broad range of direct suppliers from various locations and industries, including those generally considered a higher risk for modern slavery by virtue of their sector or geography. Based on an internal assessment, the following categories within our supply chain are considered to have increased modern slavery risk, irrespective of geographic location or the specific supplier:
We consider the above sectors to have a heightened risk profile due to their use generally of lower-skilled workers (possibly some on temporary visas, which may further increase the potential risk) often with limited ability to negotiate their wages and rights in the workplace. Another factor that contributes to modern slavery risk generally in some of these sectors is the potential for modern slavery in the upstream supply chain.

Additionally, some of our suppliers have a global footprint and, accordingly, could potentially present a higher risk of modern slavery due to operating in higher risk regions. Pfizer is currently focusing on suppliers within targeted high-risk regions and high-risk sectors as identified by Modern Slavery Risk Indices, e.g., the Global Slavery Index, and is taking steps to address these risks as described in more detail in the next section.
Policies and Governance

Pfizer has established policies designed to mitigate modern slavery risks in our business and supply chain. We expect all our employees and suppliers to be aware of, and comply with, their obligations set out in our policies.

Pfizer’s Blue Book – our Code of Conduct – describes how we operate and guides the decisions we make, and each employee and contractor is required to adhere to these standards. The Code of Conduct specifically covers our commitment to Equity and respecting human rights (see page 27). Code of Conduct training is assigned to all new colleagues upon hire and to existing colleagues regularly. The training includes a certification to confirm that colleagues are familiar with and agree to abide by the Code of Conduct and that they understand their responsibility to report and have reported any potential violations of law, regulations, ethical standards, or Pfizer policy.

In line with the UN Guiding Principles on Business and Human Rights (Guiding Principles), Pfizer’s Human Rights Policy focuses on addressing risks that could have the most severe impact on people: our patients, our employees, the workers of our business partners, and the communities in which we operate. Our commitment to respect human rights extends throughout our operations, from lab to patient, including our diverse global supply chain of numerous local, third-party vendors. The Human Rights Policy expressly indicates Pfizer prohibits the use of all forms of modern slavery in our supply chain and business operations. Pfizer’s Human Rights Policy Statement can be found here.

As noted in last year’s Statement, in 2020 Pfizer developed a global corporate labour and ethics standard for our supplier base with a focus on modern slavery. In 2021, we rolled out this standard as part of our risk-based governance process. The scope of this standard includes suppliers
and supplier categories that provide the following types of materials and services to Pfizer: direct materials, drug substances, and drug products, warehousing and distribution, contract manufacturing organizations, and services conducted on Pfizer manufacturing premises (including contracted labour services). The standard includes requirements for mitigating potential risk of harm to people arising from violation of human rights and labour standards. The standard sets out a program to assess suppliers in Pfizer’s manufacturing supply chain, including a risk-based assessment process that results in a supplier risk score (i.e., acceptable risk, high risk, or priority high risk). Suppliers that are determined to be high risk or priority high risk are subject to a more in-depth human rights assessment as part of determining whether to on-board them as a supplier, and if onboarded, periodically thereafter.

Pfizer also continues to have an active Modern Slavery working group, consisting of members from various functions including legal, procurement, Global Health & Social Impact, and Global EHS. This working group is responsible for implementing the actions set out in this Statement, developing further actions, and monitoring Pfizer’s modern slavery commitments.

Audits

Globally, Pfizer audits the potential for EHS and labour and ethics risks, including modern slavery, in its direct material supply chain. Labour and Ethics audits are completed by independent third-party auditors engaged by Pfizer in high-risk jurisdictions and by internally trained Pfizer colleagues in other instances. The auditors follow Pharmaceutical Supply Chain Initiative (PSCI) standard audit protocols, which include standard labour and ethics criteria and involve interviews with employees, contracted staff, and management. In 2021, Pfizer conducted a combination of 122 remote and on-site Supplier EHS audits, all of which were announced, with 34 of these including Labour and Ethics audits based on the supplier risk profile as determined by the risk assessment. Of the suppliers audited, five were identified as not meeting Pfizer's expectations for EHS performance, which resulted in Pfizer not pursuing or continuing business with these suppliers. We shared our observations and encouraged these suppliers to take the appropriate remedial action. There has also been other work in this area with other suppliers to establish corrective action plans to mitigate identified risks, including modern slavery risks, and we continue to monitor their implementation of agreed actions.

Anti-Bribery and Anti-Corruption

Corruption is a red flag for modern slavery risks. Pfizer has extensive international anti-bribery and anti-corruption policies and procedures in place to help ensure that employees comply with all anti-bribery and corruption laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, the U.K. Bribery Act, the Australian Commonwealth Criminal Code, the People’s Republic of China Criminal Law, and the laws of the other countries that have signed the United Nations Convention Against Corruption (UNCAC). Our policies and procedures cover, among other things, employees’ interactions with government officials and non-U.S. healthcare professionals, as well as third parties that provide goods or services to Pfizer.

These policies and procedures are reinforced through anti-corruption training and tested through periodic auditing and monitoring. Where appropriate, third parties are required to undergo anti-corruption due diligence and auditing, follow Pfizer’s internal anti-bribery and anti-corruption policies and procedures, receive anti-corruption training, and/or abide by Pfizer’s International Anti-Bribery and Anti-Corruption Business Principles.⁵

⁵ Additional information about Pfizer’s Compliance and Ethics Program is available at Pfizer.com.
Supplier Conduct Position Statement

Pfizer continues to encourage our suppliers to support our Supplier Conduct Principles or adopt their own codes that include expectations similar to ours.

- Download Pfizer’s Supplier Conduct Position Statement (PDF)
- Download Pfizer’s Supplier Conduct Principles (PDF)

Among other things, the Supplier Conduct Principles ask suppliers to:

- operate in full compliance with all applicable laws, rules, and regulations;
- conduct their business in an ethical manner, acting with integrity;
- commit to upholding the human rights of workers and to treat them with dignity and respect, including adhering to express prohibitions against the use of forced, bonded or indentured labour, and child labour; and
- provide a safe and health work environment.

Failure to comply with our Supplier Conduct Principles may result in business relationship termination.

Contract Clauses

Pfizer has modern slavery clauses in all current standard form global agreements for procuring goods and services.

Training

In 2021, procurement colleagues supporting our manufacturing and supply operations were required to take training on our Labour and Ethics Standard. In addition, our colleagues in audit, labour and ethics program oversight, human rights, and Legal who support our Modern Slavery program were trained on SA8000, a voluntary, auditable certification standard that encourages organizations to develop, maintain, and apply socially acceptable practices in the workplace.

External Engagement

Pfizer is a co-founder and active member of the Pharmaceutical Supply Chain Initiative (PSCI), an organization of pharmaceutical companies that has established a set of principles to aide pharmaceutical suppliers in establishing sustainable business practices, including ethical and responsible labour practices. PSCI’s Principles for Responsible Supply Chain Management regarding labour state that suppliers shall not use forced, bonded, indentured, or child labour.
Pfizer is a member and contributor to various PSCI committees including the Human Rights and Labour, Governance, Audit, Environmental, Scope 3, Process Safety, Worker Safety and Occupational Hygiene committees. We also chair the Partnerships Committee. We actively encourage our direct material suppliers to participate in capability-building conferences and webinars. For example, in 2021 PSCI conducted training sessions in India on:

- Changes to Indian Labour Laws;
- Migrant Labour Protection During Covid
- Human Right Due Diligence – Challenges and Developments in India.

Pfizer is also a long-standing member of Business for Social Responsibility (BSR), an organization that works with its global network of leading companies to create a just and sustainable world. Pfizer is an active contributor to BSR’s Human Rights Working Group (HRWG). The HRWG is a collaborative initiative convening companies supporting each other on implementing the Guiding Principles. Practitioners in the group represent more than 50 cross-industry companies partnering to advance and refine human rights programs at each participant company.

Additional information about Pfizer’s environmental, social, and governance (ESG) priorities are set out in Pfizer’s 2021 ESG Report and 2021 Annual Report.
Specific Examples of Due Diligence

Rubber Gloves

Pfizer has been following the United States Customs and Border Protection (USCBP) Withhold Release Orders (WROs) against multiple disposable rubber glove companies in Malaysia, including highly specialized gloves used at various Pfizer sites. The WROs apply to U.S. imports, however we instructed all of our sites globally to discontinue purchasing any gloves subject to the WROs. This is an industry-wide issue that is not unique to Pfizer, as the vast majority of disposable gloves used in the U.S. are manufactured in Malaysia by these manufacturers.

In response to the investigation by USCBP, Pfizer initiated inquiries with our distributors and certain vendors of gloves subject to WROs. Our distributors are developing alternative sources of supply for rubber gloves and expect to complete this transition in 2022.

Given this dialogue, Pfizer decided to continue to source from our distributors for certain highly specialised gloves that are critical to specific applications, but such gloves are only being supplied from manufacturers that are not subject to effective WROs.

Raising Concerns

Pfizer is dedicated to fostering an Open Door culture in which all colleagues can ask questions, raise concerns, and report potential misconduct without fear of retaliation. We measure colleague comfort and awareness about raising concerns through an anonymous culture survey sent to all colleagues annually.

Many channels exist for colleagues, contingent workers, the public, and workers in supply chains to raise questions and report concerns, including the Compliance Helpline (a third-party public hotline available by phone or web, with anonymous reporting where allowed under local law), the Compliance Division (through email, phone, fax and colleagues), management, and our Open Door Policy (i.e., whistleblower policy), which encourages colleagues to present ideas, ask questions and raise concerns.

In addition, our Office of the Ombuds is a resource to support colleagues with information and guidance to help them resolve work related issues. Pfizer’s Ombuds is informal, independent, and neutral, and is not an advocate for any party, but an advocate for fair process.
Pfizer takes seriously reports of known or suspected violations of company policies and applicable law; our goal is to respond promptly to all questions and reported concerns. We aim to identify and address any potential inappropriate conduct as early as possible, prevent future recurrences, and inform continuous improvement. Pfizer's Compliance Division investigates all significant potential, suspected or actual violations of applicable law or company policy.

Pfizer's Code of Conduct – which is publicly and internally accessible online – sets out the different reporting mechanisms described above (see page 9).

Additionally, the Global Security Operations Centre is available with 24-hour contact for any issue that concerns an immediate violence or threat or other serious situation.
In accordance with the UK Modern Slavery Act and guidance thereunder, and solely for purposes of compliance with that Act, this 2021 Modern Slavery Statement was approved on 24 August 2022 by the directors of the following:

- Pfizer Limited
- Hospira UK Limited
- John Wyeth & Brother Limited
- Pharmacia Limited
- Pfizer Development Services (UK) Limited
- Pfizer R&D UK Limited

James Pearson
Director, Pfizer Limited
24 August 2022